Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03322540 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 154
- Enrollment target
NCT03322540 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 154 participants.
The verdict
NCT03322540, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 154 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1).
Interventions
- DRUG Pembrolizumab
- DRUG Placebo
- DRUG Epacadostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2020-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03322540
The ClinicalTrials.gov registry entry for NCT03322540 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03322540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03322540 about?
NCT03322540 is a clinical study titled "Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)". The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell death ligand 1 (PD-L1).
What is the current status of trial NCT03322540?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 154 participants. The study started on 2017-12-15. Estimated completion is 2020-11-09.
What interventions are being tested in trial NCT03322540?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Epacadostat (DRUG).
Who is sponsoring clinical trial NCT03322540?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.